U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from GEO Profiles

Items: 1 to 20 of 114

1.
Targeting lysine demethylase 6B ameliorates ASXL1 truncation–mediated myeloid malignancies in preclinical models
Guo Ge, Peng Zhang, Pinpin Sui, Shi Chen, Hui Yang, Ying Guo, Ivan P. Rubalcava, Asra Noor, Caroline R. Delma, Joel Agosto-Peña, Hui Geng, Edward A. Medina, Ying Liang, Stephen D. Nimer, Ruben Mesa, Omar Abdel-Wahab, Mingjiang Xu, Feng-Chun Yang
J Clin Invest. 2024 Jan 2; 134(1): e163964. Published online 2024 Jan 2. doi: 10.1172/JCI163964
PMCID:
PMC10760961
AbstractArticlePDF–12M
2.
Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1
Jonathan F. Thomas, Marco Igor Valencia-Sánchez, Simone Tamburri, Susan L. Gloor, Samantha Rustichelli, Victoria Godínez-López, Pablo De Ioannes, Rachel Lee, Stephen Abini-Agbomson, Kristjan Gretarsson, Jonathan M. Burg, Allison R. Hickman, Lu Sun, Saarang Gopinath, Hailey F. Taylor, Zu-Wen Sun, Ryan J. Ezell, Anup Vaidya, Matthew J. Meiners, Marcus A. Cheek, William J. Rice, Vladimir Svetlov, Evgeny Nudler, Chao Lu, Michael-Christopher Keogh, Diego Pasini, Karim-Jean Armache
Sci Adv. 2023 Aug; 9(32): eadg9832. Published online 2023 Aug 9. doi: 10.1126/sciadv.adg9832
PMCID:
PMC10411902
AbstractArticlePDF–1.6M
3.
Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia
Daniel R. Richardson, David M. Swoboda, Dominic T. Moore, Steven M. Johnson, Onyee Chan, Jonathan Galeotti, Sonia Esparza, Mohammad O. Hussaini, Hendrick Van Deventer, Matthew C. Foster, Catherine C. Coombs, Nathan D. Montgomery, David A. Sallman, Joshua F. Zeidner
Am J Hematol. Author manuscript; available in PMC 2023 Jun 21.
Published in final edited form as: Am J Hematol. 2021 Apr 1; 96(4): 462–470. Published online 2021 Feb 15. doi: 10.1002/ajh.26110
PMCID:
PMC10284351
AbstractArticlePDF–957K
4.
Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression
Xin Yan, Zefeng Xu, Peihong Zhang, Qi Sun, Yujiao Jia, Tiejun Qin, Shiqiang Qu, Lijuan Pan, Zhanqi Li, Jinqin Liu, Zhen Song, Qingyan Gao, Meng Jiao, Jingye Gong, Huijun Wang, Bing Li, Zhijian Xiao
Blood Cancer J. 2023 Dec; 13(1): 56. Published online 2023 Apr 20. doi: 10.1038/s41408-023-00829-3
PMCID:
PMC10119377
ArticlePDF–1.0M
5.
Structural basis of histone H2A lysine 119 deubiquitination by Polycomb Repressive Deubiquitinase BAP1/ASXL1
Jonathan F. Thomas, Marco Igor Valencia-Sánchez, Simone Tamburri, Susan L. Gloor, Samantha Rustichelli, Victoria Godínez-López, Pablo De Ioannes, Rachel Lee, Stephen Abini-Agbomson, Kristjan Gretarsson, Jonathan M. Burg, Allison R. Hickman, Lu Sun, Saarang Gopinath, Hailey Taylor, Matthew J. Meiners, Marcus A. Cheek, William Rice, Evgeny Nudler, Chao Lu, Michael-Christopher Keogh, Diego Pasini, Karim-Jean Armache
Version 1. bioRxiv. Preprint. 2023 Feb 23. doi: 10.1101/2023.02.23.529554
Published in:
Sci Adv. 2023 Aug; 9(32): eadg9832.
PMCID:
PMC9980132
AbstractArticlePDF–30M
6.
Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
Aram Bidikian, Hagop Kantarjian, Elias Jabbour, Nicholas J. Short, Keyur Patel, Farhad Ravandi, Koji Sasaki, Ghayas C. Issa
Blood Cancer J. 2022 Oct; 12(10): 144. Published online 2022 Oct 28. doi: 10.1038/s41408-022-00742-1
PMCID:
PMC9616867
AbstractArticlePDF–818K
7.
MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer
Natsumi Tsuboyama, Aileen Patricia Szczepanski, Zibo Zhao, Lu Wang
Genome Biol. 2022; 23: 206. Published online 2022 Sep 30. doi: 10.1186/s13059-022-02776-x
PMCID:
PMC9523997
AbstractArticlePDF–6.9M
8.
High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients
Yasser H El Nahass, Heba A Nader, Salwa Sabet, Hend A Nooh, Heba Bassiony, Mahmoud Kamel, Mohamed A Samra, Hossam K Mahmoud, Wafaa H El Metnawy, Fatma A El Refaey
Asian Pac J Cancer Prev. 2022 Mar; 23(3): 977–984. doi: 10.31557/APJCP.2022.23.3.977
PMCID:
PMC9360955
AbstractArticlePDF–412K
9.
Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran
Mohammad Parsa‐kondelaji, Hossein Ayatollahi, Mehrdad Rostami, Maryam Sheikhi, Faezeh Barzegar, Monnavar Afzalaghaee, Elmira Moradi, Mohammad Hadi Sadeghian, Amir Abbas Momtazi‐Borojeni
J Cell Mol Med. 2022 Jul; 26(13): 3797–3801. Published online 2022 Jun 12. doi: 10.1111/jcmm.17424
PMCID:
PMC9258702
AbstractArticlePDF–430K
10.
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
Paola Guglielmelli, Giacomo Coltro, Francesco Mannelli, Giada Rotunno, Giuseppe G. Loscocco, Carmela Mannarelli, Chiara Maccari, Chiara Paoli, Simone Romagnoli, Niccolò Bartalucci, Alessandro M. Vannucchi
Blood Adv. 2022 May 10; 6(9): 2927–2931. Published online 2022 May 9. doi: 10.1182/bloodadvances.2021006350
PMCID:
PMC9092422
ArticlePDF–839K
11.
ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome
Robert R. West, Katherine R. Calvo, Lisa J. Embree, Weixin Wang, Laura M. Tuschong, Thomas R. Bauer, Jr, Desiree Tillo, Justin Lack, Stephenie Droll, Amy P. Hsu, Steven M. Holland, Dennis D. Hickstein
Blood Adv. 2022 Feb 8; 6(3): 793–807. Published online 2022 Jan 31. doi: 10.1182/bloodadvances.2021005065
PMCID:
PMC8945308
AbstractArticlePDF–1.4M
12.
Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia
Moritz Binder, Ryan M. Carr, Terra L. Lasho, Christy M. Finke, Abhishek A. Mangaonkar, Christopher L. Pin, Kurt R. Berger, Amelia Mazzone, Sandeep Potluri, Tamas Ordog, Keith D. Robertson, David L. Marks, Martin E. Fernandez-Zapico, Alexandre Gaspar-Maia, Mrinal M. Patnaik
Nat Commun. 2022; 13: 1434. Published online 2022 Mar 17. doi: 10.1038/s41467-022-29142-6
PMCID:
PMC8931048
AbstractArticlePDF–4.2M
13.
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation
Xiaona You, Fabao Liu, Moritz Binder, Alexis Vedder, Terra Lasho, Zhi Wen, Xin Gao, Evan Flietner, Adhithi Rajagopalan, Yun Zhou, Christy Finke, Abhishek Mangaonkar, Ruiqi Liao, Guangyao Kong, Erik A. Ranheim, Nathalie Droin, Anthony M. Hunter, Sergey Nikolaev, Maria Balasis, Omar Abdel-Wahab, Ross L. Levine, Britta Will, Kalyan Vara Ganesh Nadiminti, David Yang, Klaus Geissler, Eric Solary, Wei Xu, Eric Padron, Mrinal M. Patnaik, Jing Zhang
Blood. 2022 Feb 17; 139(7): 1066–1079. doi: 10.1182/blood.2021012519
PMCID:
PMC8854684
AbstractArticle
14.
Understanding the phenotypic spectrum of ASXL-related disease: 10 cases and a review of the literature
Vishnu Anand Cuddapah, Holly A. Dubbs, Laura Adang, Steven L. Kugler, Elizabeth M. McCormick, Zarazuela Zolkipli-Cunningham, Xilma R. Ortiz-González, Shana McCormack, Elaine Zackai, Daniel J. Licht, Marni J. Falk, Eric D. Marsh
Am J Med Genet A. Author manuscript; available in PMC 2022 Jun 1.
Published in final edited form as: Am J Med Genet A. 2021 Jun; 185(6): 1700–1711. Published online 2021 Mar 10. doi: 10.1002/ajmg.a.62156
PMCID:
PMC8842511
AbstractArticlePDF–442K
15.
Human transcription factor protein interaction networks
Helka Göös, Matias Kinnunen, Kari Salokas, Zenglai Tan, Xiaonan Liu, Leena Yadav, Qin Zhang, Gong-Hong Wei, Markku Varjosalo
Nat Commun. 2022; 13: 766. Published online 2022 Feb 9. doi: 10.1038/s41467-022-28341-5
PMCID:
PMC8828895
AbstractArticlePDF–1.7M
16.
ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen
Liang Wang, Yinfeng Lyu, Yuqing Li, Kunping Li, Hui Wen, Chenchen Feng, Ning Li
Aging (Albany NY) 2021 Sep 30; 13(18): 22286–22297. Published online 2021 Sep 18. doi: 10.18632/aging.203534
Correction in:
Aging (Albany NY). 2023 Oct 31; 15(20): 11690–11691.
PMCID:
PMC8507286
AbstractArticlePDF–1.5M
17.
Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation
Madlen Jentzsch, Juliane Grimm, Marius Bill, Johannes Küpper, Donata Backhaus, Dominic Brauer, Julia Schulz, Georg-Nikolaus Franke, Vladan Vucinic, Dietger Niederwieser, Uwe Platzbecker, Sebastian Schwind
Bone Marrow Transplant. 2021; 56(10): 2610–2612. Published online 2021 Jul 15. doi: 10.1038/s41409-021-01407-6
PMCID:
PMC8486652
ArticlePDF–598K
18.
Proteomic analysis identifies novel binding partners of BAP1
Roy Baas, Fenna J. van der Wal, Onno B. Bleijerveld, Haico van Attikum, Titia K. Sixma
PLoS One. 2021; 16(9): e0257688. Published online 2021 Sep 30. doi: 10.1371/journal.pone.0257688
PMCID:
PMC8483321
AbstractArticlePDF–2.6M
19.
Telomere Attrition and Clonal Hematopoiesis of Indeterminate Potential in Cardiovascular Disease
Yi-Chun Huang, Chao-Yung Wang
Int J Mol Sci. 2021 Sep; 22(18): 9867. Published online 2021 Sep 13. doi: 10.3390/ijms22189867
PMCID:
PMC8467562
AbstractArticlePDF–1.1M
20.
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
Nora E. Rahmani, Nandini Ramachandra, Srabani Sahu, Nadege Gitego, Andrea Lopez, Kith Pradhan, Tushar D. Bhagat, Shanisha Gordon-Mitchell, Bianca Rivera Pena, Mohammad Kazemi, Keshav Rao, Orsi Giricz, Shahina Bano Maqbool, Raul Olea, Yongmei Zhao, Jinghang Zhang, Hamid Dolatshad, Vickram Tittrea, Dharamveer Tatwavedi, Shalini Singh, Juseong Lee, Tianyu Sun, Ulrich Steidl, Aditi Shastri, Daichi Inoue, Omar Abdel-Wahab, Andrea Pellagatti, Evripidis Gavathiotis, Jacqueline Boultwood, Amit Verma
Blood Cancer J. 2021 Sep; 11(9): 157. Published online 2021 Sep 21. doi: 10.1038/s41408-021-00541-0
PMCID:
PMC8455571
AbstractArticlePDF–2.8M

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed Central (PMC)
Support Center